Ms. Consylman has been a director since 2020 and has over 25 years of experience in the fields of accounting, finance, and tax. Since May 2024, she has served as Chief Financial Officer and Chief Operating Officer of R&D at Takeda Pharmaceutical Company Limited (Takeda), where she previously served as Head, R&D Strategy & External Innovation and R&D Chief Financial Officer from June 2023 to May 2024. From April 2022 until April 2023, Ms. Consylman served as Chief Financial Officer of Vedere Bio II. She previously served as Chief Financial Officer of bluebird bio from August 2021 until April 2022, and prior to that, as Chief Financial Officer of the Severe Genetic Disease Group at bluebird bio, overseeing finance, tax, accounting, treasury, insurance and investor relations. Before joining bluebird bio, Ms. Consylman was Senior Vice President and Chief Financial Officer of Ironwood Pharmaceuticals, Inc. Prior to joining Ironwood, Gina was Vice President, Corporate Controller and Principal Accounting Officer of Analogic Corporation, a healthcare and security technology solutions company, where she led the company’s global accounting and treasury teams. Prior to Analogic, Gina held senior level accounting and corporate controller positions at Biogen Inc. and Varian Semiconductor Equipment Associates, Inc. (acquired by Applied Materials, Inc.). She began her career in public accounting at Ernst & Young LLP. From October 2018 until November 2021, Ms. Consylman served as a member of the board of directors and as chair of the audit committee of Verastem, Inc., a public biotechnology company. Ms. Consylman earned a bachelor’s degree in accounting from Johnson & Wales University and a master’s degree in taxation from Bentley University, and is a Certified Public Accountant.